Published • loading... • Updated
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
Toripalimab sales drove the gain as Junshi Biosciences also reported higher out-licensing revenue and a stronger cash position.
- On Wednesday, Shanghai Junshi Biosciences Co., Ltd. announced 2026 interim financial results showing total revenue of approximately RMB1,696 million, a 45% increase compared to 2025.
- Domestic sales of toripalimab reached approximately RMB1,299 million, around 36% more than in 2025, while out-licensing revenue surged approximately 149% to RMB152 million.
- Research and development expenses totaled approximately RMB644 million for the first half of 2026, while aggregate bank balances reached approximately RMB3,670 million as of June 30, 2026.
- Fosun Wanbang secured commercialization rights for roconkibart, or "JS005," in Greater China, with an upfront payment of RMB215 million and potential milestone payments of RMB1,125 million.
- Toripalimab has received marketing authorizations in over 50 countries, including China, the US, and Europe, positioning the company's global footprint alongside its workforce of over 3,000 employees.
Insights by Ground AI
12 Articles
12 Articles
The Toronto Star+10 Reposted by 10 other sources
Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates
SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization
·Toronto, Canada
Read Full ArticleCoverage Details
Total News Sources12
Leaning Left6Leaning Right2Center4Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
